TG Therapeutics
TGTX
113 hedge funds and large institutions have $387M invested in TG Therapeutics in 2019 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 37 increasing their positions, 29 reducing their positions, and 19 closing their positions.
93% more capital invested
Capital invested by funds: $200M → $387M (+$186M)
60% more call options, than puts
Call options by funds: $19.4M | Put options by funds: $12.1M
28% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 29
5% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 19
2% less funds holding
Funds holding: 115 → 113 (-2)
4.27% less ownership
Funds ownership: 58.98% → 54.7% (-4.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$25.9M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.55M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.91M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$4.41M |
| 5 |
EP
Eversept Partners
New York
|
+$3.69M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$19.5M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$12.3M |
| 3 |
State Street
Boston,
Massachusetts
|
-$5.76M |
| 4 |
Renaissance Technologies
New York
|
-$4.48M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$4.1M |
TGTX Hedge Fund Activity: Q1 2019 in Review
113 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q1 2019, worth a combined $387M — up 93% from $200M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of TGTX and 18 opened new positions — a net loss of 1 holder — while 29 trimmed existing stakes and 37 added.
The largest buyer was Millennium Management, adding an estimated $25.9M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $19.5M sold.
- 113 institutional investors held TG Therapeutics (TGTX) as of Q1 2019, down from 115 in Q4 2018.
- Funds reported $387M of TG Therapeutics stock for Q1 2019, up 93% quarter-over-quarter.
- 18 funds opened new TG Therapeutics positions in Q1 2019 and 19 closed out, a net change of -1 holder.
- The largest TG Therapeutics buyer in Q1 2019 was Millennium Management, an estimated $25.9M added.
- The largest TG Therapeutics seller in Q1 2019 was Avoro Capital Advisors, an estimated $19.5M sold.
Based on aggregated 13F filings for Q1 2019.